The interval from statin start date to 2014, the year of data review, did not differ between anti-HMGCRpositive (mean 11 years before 2014, SD AE 6) and anti-HMGCR-negative patients (mean 10 years before 2014, SD AE 5, p ¼ 0.65). The median duration of statin therapy before the onset of muscle symptoms was 38 months in anti-HMGCR-positive patients. More patients in the anti-HMGCR-positive group were exposed to atorvastatin (86% vs. 43%, p < 0.001).
Twenty-four patients, with equal frequency in both groups, had a history of treatment with multiple statins/combination therapy. In order to identify whether individual statins were associated with anti-HMGCR myopathy, in the multiple regression analysis, these patients were excluded. The data regarding the exact dose of statins were available for only 27 patients. However, there was no significant 
